Voyager Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Voyager Therapeutics, Inc. (VYGR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-65.00132.33-46.41-71.2036.74-43.60-88.29
Depreciation & Amortization4.734.446.195.173.82-0.782.12
Stock Based Compensation14.7911.159.3411.3214.930.000.00
Change in Working Capital34.86-66.5620.473.29-144.5496.4955.43
Change in Accounts Receivable81.31-83.230.487.2810.480.000.00
Change in Accounts Payable2.39-0.961.99-0.06-3.440.000.00
Change in Other Working Capital-48.848.23-2.47-2.21-0.910.000.00
Other Operating Activities-4.683.59-2.47-2.46-7.7015.641.30
Net Cash from Operating Activities-15.3177.92-12.51-53.53-96.7248.67-15.89
Investing Activities
Capital Expenditures-3.52-3.26-2.49-1.61-12.107.72-4.31
Purchases of Investments-465.69-138.39-54.8567.52125.090.000.00
Sales/Maturities of Investments374.3585.5850.0067.52125.09-82.9330.77
Net Cash from Investing Activities-94.86-141.64-7.3465.91113.00-90.4826.47
Financing Activities
Common Stock Issued112.7833.651.110.613.160.000.00
Other Financing Activities1.240.000.000.000.0077.620.00
Net Cash from Financing Activities114.0233.651.110.613.1680.994.75
Summary
Net Change in Cash3.85-30.08-18.7412.9919.4439.1815.33
Cash at Beginning of Period70.40100.47119.21106.2286.7847.5932.27
Cash at End of Period74.2470.40100.47119.21106.2286.7847.59
Free Cash Flow-18.8374.66-15.00-55.13-108.8141.12-20.19